

Rhythm Biosciences Secures Commercial Manufacturing Agreement for ColoSTAT[®]

Highlights

- ✓ Multi-year commercial supply agreement executed with Quansys Biosciences for ColoSTAT[®] reagent kit manufacturing.
- ✓ Agreement provides scalable manufacturing capacity to support ColoSTAT[®] Access Program and commercial rollout.
- ✓ Quansys operates ISO13485-certified manufacturing facilities with established quality systems.
- ✓ Supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.
- ✓ Agreement includes provisions for minimum order volumes and pricing framework to support anticipated operational requirements.

Melbourne, Australia, 3rd February 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce the execution of a strategic supply agreement with Quansys Biosciences, a US-based specialist manufacturer of multiplex immunoassay products.

AGREEMENT DETAILS

Under the agreement, Quansys Biosciences will serve as the contract manufacturing partner for ColoSTAT[®] consumable reagent kits, providing:

- Commercial-scale manufacturing capacity for ColoSTAT[®] reagent kits.
- ISO13485-certified production facilities with established quality management systems.
- Multi-year supply commitment supporting the ColoSTAT[®] Access Program and subsequent commercial launch.
- Flexible manufacturing capacity to scale with market demand.
- Established logistics and distribution infrastructure for global supply.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Gavin Fox-Smith	Non-Executive Chairman
Sue MacLeman	Non-Executive Director
David Atkins	CEO & Managing Director

- The agreement is funded by existing budgets and resources and includes customary termination and intellectual property provisions for a contract manufacturing agreement.

The agreement formalises a collaboration that has spanned two years of assay development, prototyping, and analytical validation activities, including evaluation of thousands of test data points. This transition to commercial manufacturing represents a significant operational milestone in ColoSTAT[®]'s path to market.

COMMERCIAL SIGNIFICANCE

The manufacturing agreement addresses a critical requirement for ColoSTAT[®]'s commercialisation by:

1. Providing reliable, quality-assured supply of consumable kits essential for test delivery.
2. Enabling the Company to support anticipated testing volumes under the ColoSTAT[®] Access Program.
3. Establishing scalable infrastructure ahead of broader commercial deployment.
4. Reducing operational risk through partnership with an experienced, certified manufacturer.
5. Fixed pricing for and initial two years providing Cost of Goods predictability with options to extend the term.

Commenting on the agreement, Rhythm Biosciences CEO & MD Dr David Atkins said:

"Securing Quansys as our commercial manufacturing partner represents a key operational milestone in ColoSTAT[®]'s commercialisation pathway. Their proven expertise in multiplex immunoassay manufacturing, combined with ISO13485-certified facilities, provides Rhythm with the quality-assured, scalable supply capacity necessary to support the ColoSTAT[®] Access Program and prepare for broader market entry. This agreement demonstrates continued progress in building the commercial infrastructure required for ColoSTAT[®] deployment. "

Quansys Biosciences CEO Adam Brown added:

"We are excited to partner with Rhythm Biosciences on ColoSTAT[®]. Quansys has built its reputation on high-quality multiplex immunoassays, backed by strong manufacturing and quality systems. The opportunity to support a transformative colorectal cancer test aligns perfectly with our mission to empower researchers and clinicians in advancing diagnosis and treatment."

NEXT STEPS

The Company continues to progress the ColoSTAT® Access Program while advancing regulatory and commercial partnership discussions. Further updates will be provided to the market as material developments occur.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About Quansys Biosciences

Quansys Biosciences is U.S.-based life sciences company specializing in multiplex immunoassay solutions, including assays, imaging instrumentation, and intuitive software for protein quantification. Headquartered in Utah, Quansys operates ISO13485 certified facilities and provides high-quality reagent kit manufacturing and contract manufacturing services to support clinical research and diagnostic development programs worldwide. Quansys is committed to maximizing data quality and throughput to help accelerate disease discovery, diagnosis, and treatment.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalised health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.